112 related articles for article (PubMed ID: 31730343)
21. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.
Wang H; Daouti S; Li WH; Wen Y; Rizzo C; Higgins B; Packman K; Rosen N; Boylan JF; Heimbrook D; Niu H
Cancer Res; 2011 Aug; 71(16):5535-45. PubMed ID: 21705440
[TBL] [Abstract][Full Text] [Related]
22. Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes.
Eblen ST; Slack JK; Weber MJ; Catling AD
Mol Cell Biol; 2002 Sep; 22(17):6023-33. PubMed ID: 12167697
[TBL] [Abstract][Full Text] [Related]
23. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
[TBL] [Abstract][Full Text] [Related]
24. MEK1 is required for PDGF-induced ERK activation and DNA synthesis in tracheal myocytes.
Karpova AY; Abe MK; Li J; Liu PT; Rhee JM; Kuo WL; Hershenson MB
Am J Physiol; 1997 Mar; 272(3 Pt 1):L558-65. PubMed ID: 9124614
[TBL] [Abstract][Full Text] [Related]
25. MEK1 and MEK2 isoforms regulate distinct functions in pancreatic cancer cells.
Zhou L; Tan X; Kamohara H; Wang W; Wang B; Liu J; Egami H; Baba H; Dai X
Oncol Rep; 2010 Jul; 24(1):251-5. PubMed ID: 20514469
[TBL] [Abstract][Full Text] [Related]
26. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
[TBL] [Abstract][Full Text] [Related]
27. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
28. RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy.
Hou J; Diao Y; Li W; Yang Z; Zhang L; Chen Z; Wu Y
Int J Pharm; 2016 May; 505(1-2):329-40. PubMed ID: 27085642
[TBL] [Abstract][Full Text] [Related]
29. Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes.
Piatelli MJ; Doughty C; Chiles TC
J Biol Chem; 2002 Apr; 277(14):12144-50. PubMed ID: 11823472
[TBL] [Abstract][Full Text] [Related]
30. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases.
Zheng CF; Guan KL
J Biol Chem; 1993 Nov; 268(32):23933-9. PubMed ID: 8226933
[TBL] [Abstract][Full Text] [Related]
31. Constitutively active mutant of the mitogen-activated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in madin-darby canine kidney-C7 cells.
Schramek H; Feifel E; Healy E; Pollack V
J Biol Chem; 1997 Apr; 272(17):11426-33. PubMed ID: 9111053
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells.
Servant MJ; Giasson E; Meloche S
J Biol Chem; 1996 Jul; 271(27):16047-52. PubMed ID: 8663242
[TBL] [Abstract][Full Text] [Related]
34. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
Hutchinson KE; Johnson DB; Johnson AS; Sanchez V; Kuba M; Lu P; Chen X; Kelley MC; Wang Q; Zhao Z; Kris M; Berger MF; Sosman JA; Pao W
Oncotarget; 2015 Sep; 6(26):22348-60. PubMed ID: 26084293
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
36. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
[TBL] [Abstract][Full Text] [Related]
37. ERK activation and mitogenesis in human airway smooth muscle cells.
Lee JH; Johnson PR; Roth M; Hunt NH; Black JL
Am J Physiol Lung Cell Mol Physiol; 2001 May; 280(5):L1019-29. PubMed ID: 11290527
[TBL] [Abstract][Full Text] [Related]
38. U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.
Smutny T; Bitman M; Urban M; Dubecka M; Vrzal R; Dvorak Z; Pavek P
Arch Toxicol; 2014 Dec; 88(12):2243-59. PubMed ID: 24819614
[TBL] [Abstract][Full Text] [Related]
39. Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models.
Daouti S; Higgins B; Kolinsky K; Packman K; Wang H; Rizzo C; Moliterni J; Huby N; Fotouhi N; Liu M; Goelzer P; Sandhu HK; Li JK; Railkar A; Heimbrook D; Niu H
Mol Cancer Ther; 2010 Jan; 9(1):134-44. PubMed ID: 20053779
[TBL] [Abstract][Full Text] [Related]
40. Allosteric modulators of MEK1: drug design and discovery.
Shang J; Lu S; Jiang Y; Zhang J
Chem Biol Drug Des; 2016 Oct; 88(4):485-97. PubMed ID: 27115708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
